Enoxaparin Sodium

• Intermediate versus standard dose enoxaparin to prevent venous thromboembolism in severe trauma patients: a multicenter double blind randomi… Pending
  2025-522832-16-00 Phase II/III 1 country Centre Hospitalier Universitaire Grenoble Alpes
• Low-dose versus standard-dose anticoagulation with argatroban or enoxaparin during extracorporeal membrane oxygenation controlled by anti-II… Pending
  2025-524553-13-00 Phase II 1 country Fakultni Nemocnice Ostrava
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 Phase IV 5 countries Rigshospitalet
• REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting
  2025-520478-20-00 Phase III 6 countries Regeneron Pharmaceuticals Inc.
• Study to evaluate the efficacy and safety of enoxaparin in children with slow-flow vascular problems undergoing interventional procedures Recruiting
  2025-521196-32-00 Phase III 1 country Fundacio Sant Joan De Deu
• A study to test if SRSD107 prevents venous thromboembolism events and how safe it is Recruiting
  2024-519688-16-00 Phase II 6 countries Sirius Therapeutics Inc.
• Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease. Recruiting
  2024-512475-12-01 Phase IV 1 country HUS-Yhtymae; University Of Helsinki
• DISTINCT: inDividual, targeted thrombosIS prophylaxis versus the standard ‘one size fits all’ approach in patients undergoing Total hIp or t… Recruiting
  2023-510186-98-00 Phase IV 1 country Academisch Ziekenhuis Leiden
• HepaGrowth Recruiting
  2024-516572-15-00 Phase IV 1 country Unidade Local De Saude De Sao Jose E.P.E.
• RIVACAST - RIVAroxaban versus low-molecular weight heparin in patients with lower limb trauma requiring brace or CASTing Recruiting
  2023-509905-62-00 Phase III 1 country Centre Hospitalier Universitaire D'Angers
• Comparing Anticoagulation Strategies using Unfractionated heparin, Argatroban and Low-molecular-weight heparin for Extracorporeal Membrane (… Recruiting
  2024-518702-40-00 Phase IV 1 country Medical University Of Vienna
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 Phase III 11 countries Italfarmaco S.p.A.
• A novel COMBinATorial therapy with albumin and enoxaparin in patients with decompensated cirrhosis at high-risk of poor outcome (COMBAT tria… Recruiting
  2023-507073-18-00 Phase II 4 countries European Foundation For The Study Of Chronic Liver Failure
• Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting
  2022-502426-41-00 Phase III 1 country Institut Gustave Roussy
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 Phase III 16 countries Celgene Corp.
• Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE Recruiting
  2022-500974-33-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
• Pre- vs. postoperative thromboprophylaxis for liver resection – a prospective, multicentre, randomized controlled trial (PREPOSTEROUS trial) Recruiting
  2024-519726-20-00 Phase IV 1 country Oslo University Hospital HF
• API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a P… Recruiting
  2024-513191-17-00 Phase II 1 country Centre Hospitalier Universitaire De Dijon
• A trial to learn how well REGN7508 works for preventing blood clots after a knee replacement in adult participants Ended
  2023-508602-14-00 Phase II 5 countries Regeneron Pharmaceuticals Inc.
• OPTI-TREX - Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients Ended
  2024-513650-30-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended
  2022-501470-18-00 Phase II 6 countries Regeneron Pharmaceuticals Inc.

Showing 1–21 of 21 trials